Relapsed/Refractory Solid Tumors, Cancer
INKTMiNK TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for AgenT-797 +/- pembrolizumab/nivolumab in Relapsed/Refractory Solid Tumors, Cancer. The expected timing is based on the latest available company guidance and may change.
11/3/23- Data update at SITC'23. 3/18/25- Trial completed. 11/7/25– Durable responses and ~23mt median OS data via poster at SITC'25. Move to Phase 2 trials planned. 11/14/25:- SITC 2025 data show durable responses and long-term survivors with favorable safety. Further oncology updates expected in 2026. 03/31/26:- SITC 2025 solid tumor data reiterated with >23-month median OS and durable remissions. 04/02/26:- Abstract accepted for ASGCT May 11-15, 2026 poster on cancer and ARDS. 05/12/26:- ASGCT Poster 3371 on May 14, 2026. Solid tumor NCT05108623 shows TH1 activation and tumor responses. 08/13/26:- ASGCT 2026 cancer findings were reiterated. Further oncology updates are expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.